We are happy to answer any questions you have about Roche Diabetes Care Ltd, Roche Diagnostics Ltd or Roche Products Ltd (Pharmaceuticals). Please use the form below to submit your request.
Please note, we cannot respond to questions regarding personal medical conditions. If you have specific questions relating to your own health or to your own use of Roche medicines, devices or meters, please consult your physician/doctor.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. All adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by [email protected] or calling +44 (0)1707 367554. If you need to report an adverse event with Tamiflu® (oseltamivir), please go to the Tamiflu® (oseltamivir) Adverse Event Reporting site.
To report an adverse event related to a Roche Diabetes Care product please contact the relevant Accu-Chek Careline.
To report an adverse event related to a CoaguChek meter please call 0808 100 7666 (UK) / 1 800 99 2868 (Ireland) or email [email protected].
For all other Diagnostics products please call 0808 100 1920 (UK) / 1 800 40 9564 or email [email protected]
Roche is required by law to document reports of adverse events, both for comprehensive safety monitoring of its products and also to fulfill reporting requirements to Regulatory Authorities. The information you have provided will be made anonymous, entered onto our Roche Drug Safety database by Roche Drug Safety staff, or Tata Consultancy Services staff based in India, who Roche have entered into contract with to provide drug safety monitoring services on its behalf, and processed in full compliance with UK Data Protection Legislation. It may be forwarded to the appropriate Regulatory Authorities in the UK and other countries by both Roche Drug Safety staff and Tata Consultancy Services staff who have been fully trained on Roche processes and procedures in an aggregated and anonymised format in accordance with the established guidelines. It may also be processed in the UK and other countries for the purposes of continually monitoring the safety of Roche’s medicines.
It may be forwarded to the appropriate Regulatory Authorities in the UK and other countries in accordance with the established guidelines. It may also be processed in the UK and other countries both within and outside of the EU for the purposes of continually monitoring the safety of Roche’s medicines.
Requests for information on Roche medicinal products and Foundation Medicine services by healthcare professionals may be made via the contact form below or the contact details provided on the right.
If you have a question about our medicine Ocrevus®▼(ocrelizumab) you can use our new chat service, AMII (Automated Medical Information Interface). It can provide information in response to questions from UK healthcare professionals on the Summary of Product Characteristics (SmPC) and from UK patients on the Patient Information Leaflet (PIL).